Option Care Health Inc (OPCH)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Option Care Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 23.70 $ — 25% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 22.1%
- Exp. sales growth 3Y > 5% 4.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 27.5%
- Net debt < 4x EBIT 3.1x
- EBIT positive, 10Y straight 7
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% –
- ROCE > 15% 12.9%
- Expected return > 10% 35.2%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 12.7% failed
- More than 10% revenue growth is expected for the coming year 7.0% failed
- Share count grows by less than 3% a year -3.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 16.9% failed
- Gross margin at 40% or higher and without meaningful erosion 18.1% failed
- Goodwill from acquisitions does not grow faster than revenue 46.5% passed
- Net debt below twice EBITDA 2.5 x EBITDA failed
- Operating cash flow covers the profits of the last three years 267 m passed
- Return on capital at 15% or higher, or up versus two years ago 12.9% passed
- Insiders hold at least 10% or are net buyers 1.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 20.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.88 | 1.86 – 1.92 | 5,747 | 9.6% | 9 |
| 12/31/2027 | 2.07 | 1.98 – 2.11 | 6,134 | 9.7% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.35 | 10.00 | 1,346 | 19.70 | 4.50 | 36 | 26 |
| 2025: Q1 | 0.28 | 9.90 | 1,333 | 16.30 | 3.50 | -7 | -17 |
| 2025: Q2 | 0.31 | 1.00 | 1,416 | 15.40 | 3.60 | 90 | 81 |
| 2025: Q3 | 0.32 | 1.40 | 1,435 | 12.20 | 3.60 | 139 | 158 |
| 2025: Q4 | 0.37 | 3.50 | 1,465 | 8.80 | 4.00 | 36 | 17 |
| 2026: Q1 | 0.29 | 2.30 | 1,351 | 1.30 | 3.40 | -12 | -21 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 936 | -36 | -43 | -0.37 | -35 | -32 | 608 |
| 2017 | 817 | -63 | -64 | -0.41 | -1 | -81 | 606 |
| 2018 | 1,940 | 38 | -6 | -0.04 | -20 | -144 | 584 |
| 2019 | 2,310 | 0 | -76 | -0.49 | 39 | 907 | 2,590 |
| 2020 | 3,033 | 111 | -8 | -0.04 | 127 | 1,016 | 2,647 |
| 2021 | 3,439 | 191 | 140 | 0.77 | 209 | 1,176 | 2,791 |
| 2022 | 3,945 | 240 | 151 | 0.83 | 268 | 1,386 | 3,232 |
| 2023 | 4,302 | 315 | 267 | 1.48 | 371 | 1,422 | 3,328 |
| 2024 | 4,998 | 322 | 212 | 1.23 | 323 | 1,404 | 3,422 |
| 2025 | 5,650 | 338 | 208 | 1.27 | 258 | 1,326 | 3,456 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Option Care Health, Inc. bietet Infusionsdienste zu Hause und an alternativen Standorten in den USA an.
| Employees | 8,000 |
|---|---|
| Headquarters | Bannockburn, IL |
| Address | 3000 Lakeside Drive, 60015 Bannockburn, United States |
| Phone | 312 940 2443 |
| Website | optioncarehealth.com |
| IPO Date | 15. Aug 1996 |
| ISIN | US68404L2016 |
| Stock Split | 1:4 on 02/03/2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John Charles Rademacher | CEO, President & Director | 1967 |
| Meenal Anil Sethna CPA | Executive VP & CFO | 1970 |
| Luke Whitworth | Chief Operating Officer | 1981 |
| Collin G. Smyser | General Counsel & Corporate Secretary | 1979 |
| Nicole Maggio | Senior VP, Controller & Principal Accounting Officer | 1983 |
| Brett Michalak | Chief Technology Officer | – |
| Alyssa Moy | Chief Information Officer | – |
| Stacey Mahone | Senior VP & Chief Compliance Officer | – |
| Jorge Ramirez | Senior VP of Strategy and Corporate Development | – |
| Michael Bavaro | Chief Human Resources & Chief Diversity Officer | 1978 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 6. Jul 2026 | Bhatia Prateek | EVP Sp Sales & Solutions | Other | 23,409 | 0.00 | – |
| 6. Jul 2026 | Bhatia Prateek | EVP Sp Sales & Solutions | Other | 16,386 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.